Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 224

Sort by

Sort Order Select

Journal Articles

Acalabrutinib to assail CLL in the frail

Christine E. Ryan, Matthew S. Davids

Blood (2025) 146 (26): 3131–3132.

https://doi.org/10.1182/blood.2025030747

Published: 2025

Journal Articles

Harnessing repressive LEF1/β-catenin complexes to overcome drug resistance in chronic lymphocytic leukemia

Kadriye Nehir Cosgun, Takeshi Ito, Mark Robinson, Esma Fera, Pranav Mishra, Jodi Forward, Prajish Iyer, Lili Wang, Tiziana Vaisitti, Silvia Deaglio, Maike Buchner, Hai-Hui Xue, Matthew S Davids, Markus Müschen

Blood (2025) 146 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2025-5659

Published: 2025

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL

Anja Rathgeber, Stacey Fernandes, Adi Nagler, Shuqiang Li, David Dorfman, Lars Bullinger, Matthew S Davids, Jennifer Brown, Kenneth Livak, Leif Ludwig, Catherine Wu, Livius Penter

Blood (2025) 146 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2025-3876

Published: 2025

Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood (2025) 146 (Supplement 1): 664.

https://doi.org/10.1182/blood-2025-664

Published: 2025

Journal Articles

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2025-3602

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

JAK1/2 inhibition with ruxolitinb potentiates ex vivo activity of epcoritamab in primary CLL cells

Xiao Lyu, Stephanie Chamberlain, Jeremy Zhang, Jing Wang, Nathalie Javidi-Sharifi, Matthew S Davids

Blood (2025) 146 (Supplement 1): 2106.

https://doi.org/10.1182/blood-2025-2106

Published: 2025

Journal Articles

CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies

Blood (2025) 146 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2025-1525

Published: 2025

Journal Articles

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 464.

https://doi.org/10.1182/blood-2025-464

Published: 2025

Journal Articles

Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis

Fen Zhu, Jing Wang, Christine Ryan, Liam Hackett, Jeremy Zhang, Stephen Chong, Matthew S Davids

Blood (2025) 146 (Supplement 1): 5076.

https://doi.org/10.1182/blood-2025-5076

Published: 2025

Journal Articles

Apoptotic rewiring via PI3K hyperactivation as a therapeutic strategy in B-cell malignancies

Stephen Martindale, Etienne Leveille, Jing Wang, Takeshi Ito, Kadriye Nehir Cosgun, Matthew S Davids, Markus Müschen

Blood (2025) 146 (Supplement 1): 437.

https://doi.org/10.1182/blood-2025-437

Published: 2025

Journal Articles

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Blood (2025) 146 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2025-1812

Published: 2025

Journal Articles

A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia

Salem Elias, Andrew Lu, Fuguo Liu, Xingyu Deng, Olivia Stringham, Jeremy Zhang, Nathalie Javidi-Sharifi, Lara Bencsics, Stephanie Chamberlain, Rizwan Romee, Matthew S Davids

Blood (2025) 146 (Supplement 1): 246.

https://doi.org/10.1182/blood-2025-246

Published: 2025

Journal Articles

Identification of NAE1-dependent β-catenin neddylation as selective vulnerability in B-cell malignancies

Kadriye Nehir Cosgun, Takeshi Ito, Mark Robinson, Esma Fera, Salim Oulghazi, Yanzhi Feng, Jodi Forward, Tianhao Yin, Gang Xin, Sidi Chen, Matthew S Davids, Markus Müschen

Blood (2025) 146 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2025-5042

Published: 2025

Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand

Blood (2025) 146 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2025-3913

Published: 2025

Journal Articles

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study

Matthew S Davids, Alen Ostojic, Susana Wargo, Moana Hodari, Jiefen Munley, Richard Hermann

Blood (2025) 146 (Supplement 1): 3912.

https://doi.org/10.1182/blood-2025-3912

Published: 2025

Journal Articles

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Fernanda Santos Azevedo, Kiyomi Mashima, Ava Bidgoli, Paulina Predko, Mariia Mikhaleva, Stephen Martindale, Stacey Fernandes, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2025-3906

Published: 2025

Journal Articles

Characterization of IGHV subgroups and their prognostic relevance in CLL

Daniel Sungchul Choi, Uday Aditya Sarkar, Yue Ren, Yinglu Zhou, Roberta S. Azevedo, James Yoon, Kiyomi Mashima, Fernanda Santos Azevedo, Gordon Saksena, Stacey Fernandes, Paulina Predko, Matthew S Davids, Svitlana Tyekucheva, Jennifer Brown, Inhye Ahn

Blood (2025) 146 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2025-3899

Published: 2025

Journal Articles

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials

Toby Eyre, Lisa M. Hess, Ehsan Masoudi, Min-Hua Jen, Sarang Abhyankar, Peita Graham-Clarke, Naleen Raj Bhandari, Peter Maguire, Katherine Winfree, Marsha Tracey, Kaisa-Leena Taipale, Matthew S Davids

Blood (2025) 146 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2025-5684

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib to assail CLL in the frail

Harnessing repressive LEF1/β-catenin complexes to overcome drug resistance in chronic lymphocytic leukemia

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

JAK1/2 inhibition with ruxolitinb potentiates ex vivo activity of epcoritamab in primary CLL cells

CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis

Apoptotic rewiring via PI3K hyperactivation as a therapeutic strategy in B-cell malignancies

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia

Identification of NAE1-dependent β-catenin neddylation as selective vulnerability in B-cell malignancies

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Characterization of IGHV subgroups and their prognostic relevance in CLL

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only